Compare ADMA Biologics Inc (ADMA) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Paycom Software Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Paycom Software Inc trades at $211 (market cap $9.62B). The key difference: Paycom Software Inc is far larger — about 4.4× ADMA Biologics Inc's market cap, and Paycom Software Inc pays a 0.7% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PAYC | |
|---|---|---|
Market Cap | $2.18B | $9.62B |
Sector | Health | Technology |
52-Week High | $20.38 | $233.89 |
52-Week Low | $7.60 | $113.59 |
Enterprise Value | $2.25B | $10.41B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Paycom Software (PAYC) trades at $214.94, down 0.48% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong fundamentals, including a 22.78% net income margin and consistent earnings beats, most recently with Q2 2026 EPS of $2.78 versus $2.38 expected. Recent news highlights AI-driven demand and raised 2026 guidance, fueling positive sentiment.
Outlook remains favorable due to robust profitability and growth initiatives, though risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting modest upside potential from current levels amid balanced buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
